Učitavanje...
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors
Expression of the EGF receptors (EGFRs) is abnormally high in many types of cancer, including 25% of lung cancers. Successful treatments target mutations in the EGFR tyrosine kinase domain with EGFR tyrosine kinase inhibitors (TKIs). However, almost all patients develop resistance to this treatment,...
Spremljeno u:
| Izdano u: | Future Oncol |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4375777/ https://ncbi.nlm.nih.gov/pubmed/25757687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.14.312 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|